DOCSLIB.ORG

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents Edward Li, PharmD, MPH, BCOP University of New England College of Pharmacy Learning Objectives 1. Discuss the pharmacology and indications of medications approved in the year 2016–2017 for the management of patients with solid tumors 2. Recall the pivotal clinical trial data considered by the FDA when approving new oncologics 3. Identify the signs and symptoms of serious or life-threatening adverse effects of newly approved oncology drugs 4. Describe the impact of these agents in advanced practice Financial Disclosure • Edward Li, PharmD, MPH, BCOP, declares that he has served on the speakers bureau for Pfizer and ApoBiologiX and on advisory boards for Pfizer, Eli Lilly, and Mylan. History of Cancer Drug Approvals in the United States 1942: Goodman and Gilman 1975: CMF for 1992: Paclitaxel use nitrogen mustard for NHL breast cancer FDA approved Targeted 1959: FDA approves therapies cyclophosphamide 1940s 1950s 1960s 1970s 1980s 1990s 2000s 1948: Farber 1965: 1978: 1998: 2001: Imatinib uses antifolate in Combination Cisplatin Trastuzumab FDA approved ALL chemo for ALL approved FDA approved ALL = acute lymphoblastic leukemia; CMF = cyclophosphamide, methotreXate and fluorouracil; FDA = US Food and Drug Administration; NHL = non-Hodgkin lymphoma. Adapted from Chabner BA, et al. Nat Rev Cancer 2005;5:65-72. Drug Approvals Impact the Practice Paradigm 1942: Goodman Combination and Gilman use chemo Commercialized Ta rg e te d nitrogen Expansion of regimens chemo era therapy era mustard for oral oncolytics invented begins begins NHL 1960 // 1980 1990 2000 2010 Cancer treatment paradigm Cisplatin (1978) Supportive care management: CINV Filgrastim (1991) Supportive care management: febrile neutropenia Trastuzumab (1998), imatinib (2000), gefitinib (2003), etc. Cancer pharmacogenomics 18 oral agents approved 2011–2014 PO adherence/monitoring CINV = chemotherapy-induced nausea and vomiting. Era of Immuno-Oncology First immune checkpoint First oncolytic inhibitor approved virus approved CAR T cells Cytokines First autologous cellular (interferons), etc. Expansion of PD- therapy approved First PD-1 inhibitor 1/PD-L1 indications approved 2000 // 2010 // 2012 // 2015 2016 2017 Survival outcomes Cancer treatment paradigm Severe immune-related adverse events Adverse event monitoring and treatment Serious discussion on pseudoprogression Immune-related response criteria Storage and handling Infrastructure needs IO becomes mainstream Cost containment Intensive monitoring CRS CAR = chimeric antigen receptor; CRS = cytokine-release syndrome; IO = immuno-oncology; PD-1 = programmed cell death protein 1; PD-L1 = programmed death-ligand 1. New Drug Approvals: December 2016 to September 2017 Established Mechanism Novel Mechanism Generic Brand Approval Date Generic Brand Approval Date Rucaparib Rubraca December 19, 2016 Olaratumab Lartruvo October 20, 2016 Ribociclib Kisqali March 13, 2017 Avelumab Bavencio March 23, 2017 Niraparib Zejula March 27, 2017 Brigatinib Alunbrig April 28, 2017 Durvalumab Imfinzi May 1, 2017 Neratinib NerlynX July 17, 2017 Olaparib tabs Lynparza August 17, 2017* Abemaciclib Ver z enio September 28, 2017 *Original FDA approval date: Dec. 19, 2014 US Food and Drug Administration, Hematology/Oncology (Cancer) Approvals & Safety Notifications, https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. Other Important Regulatory Events Generic Brand Event Description Event Description Date Nivolumab Opdivo Expanded indication Urothelial carcinoma Feb. 2, 2017 Osimertinib Tagrisso Acc à Reg approval T790M+ NSCLC Mar. 30, 2017 HR+, HER2-, initial advanced/metastatic breast Palbociclib Ibrance Acc à Reg approval Mar. 31, 2017 cancer with AI Regorafenib Stivarga Expanded indication Hepatocellular carcinoma Apr. 27, 2017 Accelerated Metastatic nonsquamous NSCLC with Pembrolizumab Keytruda May 10, 2017 approval carboplatin/pembrolizumab Pembrolizumab Keytruda Regular approval Urothelial carcinoma May 18, 2017 Accelerated Pembrolizumab Keytruda MSI-H or dMMR solid tumors May 23, 2017 approval Ceritinib Zykadia Acc à Reg approval ALK+ NSCLC May 26, 2017 AI = aromatase inhibitor; ALK = anaplastic lymphoma kinase; dMMR = mismatch repair deficient; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; MSI-H = microsatellite instability high; NSCLC = non–small call lung cancer. US Food and Drug Administration, Hematology/Oncology (Cancer) Approvals & Safety Notifications, https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. Other Important Regulatory Events Generic Brand Event Description Event Description Date Dabrafenib + Tafinlar + Regular approval BRAF V600E mutated NSCLC June 22, 2017 trametinib Mekinist Nivolumab Opdivo Accelerated approval MSI-H or dMMR met colorectal cancer Aug. 1, 2017 Bevacizumab- Mvasi Biosimilar approval CRC, NSCLC, GBM, RCC, cervical Sep. 14, 2017 awwb CabazitaXel Jevtana Lower dose CRPC in combination with prednisone Sep. 14, 2017 PD-L1+, advanced/metastatic gastric/GE junction Pembrolizumab Keytruda Accelerated approval Sep. 22, 2017 adenocarcinoma Nivolumab Opdivo Accelerated approval Hepatocellular carcinoma Sep. 22, 2017 CRC = colorectal cancer; CRPC = castration-resistant prostate cancer; GBM = glioblastoma; GE = gastroesophageal; RCC = renal cell carcinoma. US Food and Drug Administration, Hematology/Oncology (Cancer) Approvals & Safety Notifications, https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. New Drug Approvals: December 2016 to September 2017 Route of Administration Generic Brand Approval Date Rucaparib Rubraca December 19, 2016 Ribociclib Kisqali March 13, 2017 Avelumab Bavencio March 23, 2017 Niraparib Zejula March 27, 2017 Parenteral (IV) Brigatinib Alunbrig April 28, 2017 Oral administration administration Durvalumab Imfinzi May 1, 2017 Neratinib NerlynX July 17, 2017 Olaparib tabs Lynparza August 17, 2017* September 28, Abemaciclib Verzenio *Original FDA approval date: Dec. 19, 2014 2017 US Food and Drug Administration, Hematology/Oncology (Cancer) Approvals & Safety Notifications, https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. New Drug Approvals: December 2016 to September 2017 PARP Inhibitors FDA-Approved Indications Generic Brand Approval Date Rucaparib Rubraca December 19, 2016 Monotherapy for the treatment of patients with Ribociclib Kisqali March 13, 2017 deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer; Avelumab Bavencio March 23, 2017 treated with two or more chemotherapies Niraparib Zejula March 27, 2017 Brigatinib Alunbrig April 28, 2017 Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal Durvalumab Imfinzi May 1, 2017 cancer who are in a complete or partial Neratinib Nerlynx July 17, 2017 response to platinum-based chemotherapy Olaparib tabs Lynparza August 17, 2017* *Original FDA approval date: Dec. 19, 2014 Abemaciclib Ver zenio September 28, 2017 PARP = poly ( ADP-ribose) polymerase. US Food and Drug Administration, Hematology/Oncology (Cancer) Approvals & Safety Notifications, https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. Pharmacology of PARP Inhibition Role in Synthetic Lethality Other Functions of PARP Reprinted by permission from Macmillan Publishers Ltd: Sonnenblick A, et al. Nat Rev Clin Oncol 2015;12:27-41, copyright 2015. PARP Inhibitor Clinical Trials (Landmark) Agent (Activity) Study Design Dosing Reference Rucaparib Phase 2 open-label study of rucaparib in 600 mg orally twice daily NCT018913441 (PARP 1/2) recurrent platinum-sensitive disease (3+ continuously as monotherapy lines of chemo) stratified according to homologous recombination deficiency (n = 206) Niraparib Randomized phase 3 study of niraparib vs. Niraparib 300 mg orally daily NCT018472742 (PARP 1/2) placebo for maintenance in recurrent, within 8 weeks after completing platinum-sensitive disease (n = 553) last dose of platinum-based chemotherapy Olaparib Randomized phase 2 study of olaparib vs. Olaparib 400 mg orally twice daily NCT007535453 (PARP 1/2/3) placebo for maintenance in recurrent, within 8 weeks after completing platinum-sensitive disease (n = 265) last dose of platinum-based chemotherapy 1. Swisher EM, et al. Lancet Oncol 2017;18:75-87; 2. Mirza MR, et al. N Engl J Med 2016;375:2154-64; 3. Ledermann JA, et al. Lancet Oncol 2016;17:1579-89. Rucaparib for Recurrence: ARIEL2 BRCA Wild-Type and BRCA Wild-Type and BRCA Mutation+ LOH High LOH Low Outcome n = 40 n = 82 n = 70 ORR, % 80% 29% 10% Progression-free survival Median 12.8 months 5.7 months 5.2 months HR (vs. LOH-low) 0.27 0.62 -- (95% CI) (0.16–0.44) (0.42–0.90) -- p value < .0001 .011 -- Duration of response 9.2 months 10.8 months 5.6 months Median 6.4–12.9 5.7–NR 4.6–8.5 (95% CI) .013 .022 p value (vs. LOH-low) CI = confidence interval; HR = hazard ratio; LOH = loss of heterozygosity; ORR = objective response rate. Swisher EM, et al. Lancet Oncol 2017;18:75-87. Niraparib, Olaparib for Maintenance Mirza et al., 2016 Ledermann et al., 2016 Phase 3 Phase 2 Outcome Niraparib Niraparib (BRCA mutations vs. BRCA BRCA wt and Niraparib Olaparib Olaparib wild-type) mut(+) HRD BRCA wt BRCA mut(+) BRCA wt Progression-free survival HR 0.27 0.38 0.45 0.18 0.54 (95% CI) (0.17–0.41) (0.24–0.59) (0.34–0.61) (0.10–0.31) (0.34–0.85) Median, mo (vs. placebo) 21.0 vs. 5.5 12.9 vs. 3.8 9.3 vs. 3.9 11.2 vs. 4.3 7.4 vs. 5.5 p-value p < .001 p
Load more

Recommended publications
  • New Drug Update: the Next Step in Personalized Medicine
    New Drug Update: The Next Step in Personalized Medicine Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist WVU Medicine Mary Babb Randolph Cancer Center Objectives • Review indications for new FDA approved anti- neoplastic medications in 2017 • Outline place in therapy of new medications • Become familiar with mechanisms of action of new medications • Describe adverse effects associated with new medications • Summarize dosing schemes and appropriate dose reductions for new medications First-in-Class Approvals • FLT3 inhibitor – midostaurin • IDH2 inhibitor – enasidenib • Anti-CD22 antibody drug conjugate – inotuzumab ozogamicin • CAR T-cell therapy - tisagenlecleucel “Me-too” Approvals • CDK 4/6 inhibitor – ribociclib and abemaciclib • PD-L1 inhibitors • Avelumab • Durvalumab • PARP inhibitor – niraparib • ALK inhibitor – brigatinib • Pan-HER inhibitor – neratinib • Liposome-encapsulated combination of daunorubicin and cytarabine • PI3K inhibitor – copanlisib Drugs by Malignancy AML Breast Bladder ALL FL Lung Ovarian 0 1 2 3 Oral versus IV 46% 54% Oral IV FIRST-IN CLASS FLT3 Inhibitor - midostaurin Journal of Hematology & Oncology 2017;10:93 Midostaurin (Rydapt®) • 717 newly diagnosed FLT3+ AML Patients • Induction and consolidation chemotherapy and placebo maintenance versus chemotherapy + midostaurin and Treatment maintenance midostaurin • OS: 74.7 mo versus 25.6 mo (P=0.009) Efficacy • EFS: 8.2 mo versus 3.0 mo (P=0.002) • Higher grade > 3 anemia, rash, and nausea Safety N Engl J Med 2017;377:454-64 Midostaurin (Rydapt®) • Approved indications: FLT3+ AML, mast cell leukemia, systemic mastocytosis • AML dose: 50 mg twice daily with food on days 8-21 • Of each induction cycle (+ daunorubicin and cytarabine) • Of each consolidation cycle (+ high dose cytarabine) • ADEs: nausea, myelosuppression, mucositis, increases in LFTs, amylase/lipase, and electrolyte abnormalities • Pharmacokinetics: hepatic metabolism, substrate of CYP 3A4; < 5% excretion in urine RYDAPT (midostaurin) [package insert].
    [Show full text]
  • First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
    First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations Patients with stage IV non-small cell lung cancer Nonsquamous cell carcinoma and squamous cell carcinoma Activating EGFR mutation other Sensitizing (L858R/exon 19 MET exon 14 skipping than exon 20 insertion mutations, EGFR exon 20 mutation ALK rearrangement ROS1 rearrangement BRAF V600E mutation RET rearrangement NTRK rearrangement mutations KRAS alterations HER2 alterations NRG1 alterations deletion) EGFR mutation T790M, L858R or Ex19Del PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Emerging target; no Emerging target; no Emerging target; no Platinum doublet † † † Osimertinib monotherapy S Afatinib monotherapy M M Alectinib S Entrectinib M Dabrafenib/trametinib M Capmatinib M Selpercatinib M Entrectinib M conclusions available conclusions available conclusions available chemotherapy ± bevacizumab Gefitinib with doublet Standard treatment based on Standard treatment based on Standard treatment based on M M M Brigatinib S Crizotinib M M Tepotinib M Pralsetinib* W Larotrectinib M chemotherapy non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline If alectinib or brigatinib are not available If entrectinib or crizotinib are not available Standard treatment based on Standard treatment based on Standard treatment based on Dacomitinib monotherapy M Osimertinib W M M M Ceritinib S Ceritinib W non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline Monotherapy with afatinib M Crizotinib S Lortlatinib W Standard treatment based on Erlotinib/ramucirumab M M non-driver mutation guideline Erlotinib/bevacizumab M Monotherapy with erlotinib M Strength of Recommendation Monotherapy with gefitinib M S Strong M Moderate W Weak Monotherapy with icotinib M Notes.
    [Show full text]
  • Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    cancers Review Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Tri Le 1 and David E. Gerber 1,2,3,* 1 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA; [email protected] 2 Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA 3 Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA * Correspondence: [email protected]; Tel.: +1-214-648-4180; Fax: +1-214-648-1955 Received: 15 January 2019; Accepted: 4 March 2019; Published: 15 March 2019 Abstract: The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, controlled, double-blind trial of treatment-naïve patients with EGFR mutant NSCLC, osimertinib was compared to standard-of-care EGFR TKIs (i.e., erlotinib or gefinitib) in the first-line setting. Osimertinib demonstrated improvement in median progression-free survival (18.9 months vs. 10.2 months; hazard ratio 0.46; 95% CI, 0.37 to 0.57; p < 0.001) and a more favorable toxicity profile due to its lower affinity for wild-type EGFR. Furthermore, similar to later-generation anaplastic lymphoma kinase (ALK) inhibitors, osimertinib has improved efficacy against brain metastases. Despite this impressive effect, the optimal sequencing of osimertinib, whether in the first line or as subsequent therapy after the failure of earlier-generation EGFR TKIs, is not clear.
    [Show full text]
  • Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer
    ARTICLE Received 29 Sep 2016 | Accepted 30 Jan 2017 | Published 13 Mar 2017 DOI: 10.1038/ncomms14768 OPEN Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer Ken Uchibori1,2, Naohiko Inase2, Mitsugu Araki3, Mayumi Kamada4, Shigeo Sato1, Yasushi Okuno3,4, Naoya Fujita1 & Ryohei Katayama1 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR–TKI resistance. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR. The structure–activity relationship analysis reveals the key component in brigatinib to inhibit the triple-mutant EGFR. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR. 1 Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. 2 Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
    [Show full text]
  • Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome‐Driven Oncology
    Supplementary Online Content Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome‐driven oncology. JAMA Oncology. Published online April 17, 2018. doi:10.1001/jamaoncol.2018.1660 eAppendix 1. Yearly Cancer Statistics eAppendix 2. Data Sources by Malignancy eAppendix 3. Pie Charts Estimating Patients Eligible for Genomically Targeted Therapy eAppendix 4. Pie Charts Estimating Patients Who Could Benefit from Genomically Targeted Therapy eAppendix 5. Pie Charts Estimating Patients Eligible for Genomically Informed Therapy eAppendix 6. Pie Charts Estimating Patients Who Could Benefit from Genomically Informed Therapy eAppendix 7. Pie Charts Estimating Patients Eligible for and who could Benefit from Adjuvant Therapy eFigure 1. Percent of US metastatic Cancer Patients Who May be Eligible for and Benefit from Genomically Informed Treatment eFigure 2. Growth of Genome Targeted and Informed Therapy Over Time With Fitted Linear Regression This supplementary material has been provided by the authors to give readers additional information about their work. 1 © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eAppendix 1. Cancer Statistics by Year: 2006: https://www.ncbi.nlm.nih.gov/pubmed/16514137 2007: https://www-ncbi-nlm-nih-gov/pubmed/17237035 2008: https://www-ncbi-nlm-nih-gov/pubmed/18287387 2009: https://www-ncbi-nlm-nih-gov/pubmed/19474385 2010: https://www-ncbi-nlm-nih-gov/pubmed/20610543 2011: https://www.ncbi.nlm.nih.gov/pubmed/21685461 2012: https://www.ncbi.nlm.nih.gov/pubmed/22237781 2013: https://www.ncbi.nlm.nih.gov/pubmed/23335087 2014: https://www.ncbi.nlm.nih.gov/pubmed/24890451 2015: https://www.ncbi.nlm.nih.gov/pubmed/25559415 2016: https://www.ncbi.nlm.nih.gov/pubmed/26742998 2017: https://www.ncbi.nlm.nih.gov/pubmed/28055103 2018: https://www.ncbi.nlm.nih.gov/pubmed/29313949 eAppendix 2.
    [Show full text]
  • Oncology Oral, Lung Cancer Therapeutic Class Review (TCR)
    Oncology Oral, Lung Cancer Therapeutic Class Review (TCR) April 14, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. April 2020 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2010–2020 Magellan Rx Management. All rights reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors alectinib Genentech .
    [Show full text]
  • The New-Generation Selective ROS1/NTRK Inhibitor DS-6051B Overcomes Crizotinib Resistant ROS1- G2032R Mutation in Preclinical Models
    ARTICLE https://doi.org/10.1038/s41467-019-11496-z OPEN The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1- G2032R mutation in preclinical models Ryohei Katayama 1, Bo Gong1,2, Noriko Togashi 3, Masaya Miyamoto3, Masaki Kiga3, Shiho Iwasaki3, Yasuki Kamai3, Yuichi Tominaga3, Yasuyuki Takeda3, Yoshiko Kagoshima3, Yuki Shimizu1,2, Yosuke Seto1, Tomoko Oh-hara1, Sumie Koike1, Naoki Nakao4, Hiroyuki Hanzawa4, Kengo Watanabe 3, Satoshi Yoda 5,6, Noriko Yanagitani7, Aaron N. Hata5,6, Alice T. Shaw5,6, Makoto Nishio7, Naoya Fujita1,2 & Takeshi Isoyama 3 1234567890():,; ROS1 gene rearrangement was observed in around 1–2 % of NSCLC patients and in several other cancers such as cholangiocarcinoma, glioblastoma, or colorectal cancer. Crizotinib, an ALK/ROS1/MET inhibitor, is highly effective against ROS1-rearranged lung cancer and is used in clinic. However, crizotinib resistance is an emerging issue, and several resistance mechanisms, such as secondary kinase-domain mutations (e.g., ROS1-G2032R) have been identified in crizotinib-refractory patients. Here we characterize a new selective ROS1/NTRK inhibitor, DS-6051b, in preclinical models of ROS1- or NTRK-rearranged cancers. DS-6051b induces dramatic growth inhibition of both wild type and G2032R mutant ROS1–rearranged cancers or NTRK-rearranged cancers in vitro and in vivo. Here we report that DS-6051b is effective in treating ROS1- or NTRK-rearranged cancer in preclinical models, including crizotinib-resistant ROS1 positive cancer with secondary kinase domain mutations especially G2032R mutation which is highly resistant to crizotinib as well as lorlatinib and entrectinib, next generation ROS1 inhibitors. 1 Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
    [Show full text]
  • Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
    cancers Review Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies Alberto D’Angelo 1,* , Navid Sobhani 2 , Robert Chapman 3 , Stefan Bagby 1, Carlotta Bortoletti 4, Mirko Traversini 5, Katia Ferrari 6, Luca Voltolini 7, Jacob Darlow 1 and Giandomenico Roviello 8 1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK; [email protected] (S.B.); [email protected] (J.D.) 2 Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; [email protected] 3 University College London Hospitals NHS Foundation Trust, 235 Euston Rd, London NW1 2BU, UK; [email protected] 4 Department of Dermatology, University of Padova, via Vincenzo Gallucci 4, 35121 Padova, Italy; [email protected] 5 Unità Operativa Anatomia Patologica, Ospedale Maggiore Carlo Alberto Pizzardi, AUSL Bologna, Largo Bartolo Nigrisoli 2, 40100 Bologna, Italy; [email protected] 6 Respiratory Medicine, Careggi University Hospital, 50139 Florence, Italy; [email protected] 7 Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla, 1, 50134 Florence, Italy; luca.voltolini@unifi.it 8 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy; [email protected] * Correspondence: [email protected] Received: 22 September 2020; Accepted: 5 November 2020; Published: 6 November 2020 Simple Summary: Genetic rearrangements of the ROS1 gene account for up to 2% of NSCLC patients who sometimes develop brain metastasis, resulting in poor prognosis. This review discusses the tyrosine kinase inhibitor crizotinib plus updates and preliminary results with the newer generation of tyrosine kinase inhibitors, which have been specifically conceived to overcome crizotinib resistance, including brigatinib, cabozantinib, ceritinib, entrectinib, lorlatinib and repotrectinib.
    [Show full text]
  • Unitedhealthcare Cancer Therapy Pathways Program Regimens
    UnitedHealthcare Cancer Therapy Pathways Program Overview 2 Breast Cancer 3 Pancreatic Cancer 15 Melanoma 19 Colon/Rectal Cancer 23 Hepatobiliary Cancers 30 Lung Cancer, Small Cell 35 Lung Cancer, Non-Small Cell 40 Ovarian, Fallopian and Primary Peritoneal Cancer 56 Head and Neck Cancer 67 Multiple Myeloma 74 Lymphoma, Diffuse Large B-Cell 86 Lymphoma, Follicular 92 Lymphoma, Marginal Zone 97 Lymphoma, Mantle Cell 101 Change control 1 OVERVIEW Cancer Therapy Pathways Program With the rapid approval of new therapies, along with the rising cost of cancer care, pathways serve a critical role in the delivery of high-quality and high-value cancer treatments while reducing an unwarranted variation in care. The UnitedHealthcare Cancer Therapy Pathways Program aims to improve quality and value in cancer care by identifying anti-cancer regimens supported by evidence-based guidelines to help reduce total cost of care and improve outcomes. The program’s regimens are selected on the basis of clinical benefit (efficacy) and side-effect profile (toxicity). Among regimens with comparable efficacy and toxicity, additional consideration is given to the frequency of hospitalizations during therapy, duration of therapy, drug costs and total cost of care. Care decisions are between the physician and the patient The Cancer Therapy Pathways Program is not a substitute for the experience and judgment of a physician or other health care professional. Any clinician participating in the program must use independent medical judgment in the context of individual
    [Show full text]
  • Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
    REVIEWS Kinase drug discovery 20 years after imatinib: progress and future directions Philip Cohen 1 ✉ , Darren Cross 2 ✉ and Pasi A. Jänne 3 ✉ Abstract | Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or mutations in their genes, cause cancer and other diseases. Here, we review the remarkable progress made over the past 20 years in improving the potency and specificity of small-molecule inhibitors of protein and lipid kinases, resulting in the approval of more than 70 new drugs since imatinib was approved in 2001. These compounds have had a significant impact on the way in which we now treat cancers and non- cancerous conditions. We discuss how the challenge of drug resistance to kinase inhibitors is being met and the future of kinase drug discovery. Protein kinases In 2001, the first kinase inhibitor, imatinib, received FDA entered clinical trials in 1998, changed the perception Enzymes that catalyse transfer approval, providing the catalyst for an article with the of protein kinases as drug targets, which had previously of the γ- phosphate of ATP provocative title ‘Protein kinases — the major drug tar- received scepticism from many pharmaceutical com- to amino acid side chains in gets of the twenty- first century?’1. Imatinib inhibits the panies. Since then, hundreds of protein kinase inhibi- substrate proteins, such as serine, threonine and tyrosine Abelson (ABL) tyrosine kinase, which is expressed as a tors have been developed and tested in humans and, at residues. deregulated fusion protein, termed BCR–ABL, in nearly the time of writing, 76 have been approved for clinical all cases of chronic myeloid leukaemia (CML)2 and is use, mainly for the treatment of various cancers (FiG.
    [Show full text]
  • The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
    pharmaceuticals Review The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer 1, 1, 1, 1 Valerio Gristina y, Maria La Mantia y , Federica Iacono y, Antonio Galvano , 1, 2, , Antonio Russo z and Viviana Bazan * z 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90127 Palermo, Italy; [email protected] (V.G.); [email protected] (M.L.M.); [email protected] (F.I.); [email protected] (A.G.); [email protected] (A.R.) 2 Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), Section of Medical Oncology, University of Palermo, 90127 Palermo, Italy * Correspondence: [email protected] These authors contributed equally to this work. y These authors are co-last. z Received: 29 October 2020; Accepted: 16 December 2020; Published: 18 December 2020 Abstract: The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm shift over the last decade. Better molecular characterization of the disease has led to the rapid improvement of personalized medicine and the prompt delivery of targeted therapies to patients with NSCLC. The discovery of the EML4-ALK fusion gene in a limited subset of patients affected by NSCLC and the subsequent clinical development of crizotinib in 2011 has been an impressive milestone in lung cancer research. Unfortunately, acquired resistances regularly develop, hence disease progression occurs. Afterward, modern tyrosine kinase inhibitors (TKIs), such as ceritinib, alectinib, brigatinib, and lorlatinib, have been approved by the Food and Drug Administration (FDA) for the management of anaplastic lymphoma kinase (ALK)-positive NSCLCs.
    [Show full text]
  • NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19
    NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 Guideline Page Panel Discussion/References Institution Vote and Request YES NO ABSTAIN ABSENT ASTR-1 Based on the data in the noted references, the panel consensus was to include 19 0 2 8 Internal request: Consider everolimus (as an example of an mTOR inhibitor) to be included as an adjuvant everolimus (as an example treatment option for patients with subependymal giant cell astrocytoma (SEGA). of an mTOR inhibitor) to be This is a category 2A recommendation. included as an adjuvant Franz DN, Belousova E, Sparagana S, et al. Everolimus for treatment option for subependymal giant cell astrocytoma in patients with tuberous sclerosis patients with subependymal complex: 2-year open-label extension of the randomised EXIST-1 study. giant cell astrocytoma Lancet Oncol 2014;15:1513-1520. (SEGA). Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-132. LEPT-2 The panel consensus was to include the changes to the treatment algorithms for 18 2 2 7 Internal request: Please leptomeningeal metastases. review the edits made to the treatment algorithms on this page for clarity. BRAIN-D (4 of 13) Based on the data in the noted reference, the panel consensus was to include 15 3 4 7 Internal request: lapatinib + temozolomide as a treatment option for progression of recurrent Should consideration of disease in patients with adult intracranial and/or spinal ependymoma.
    [Show full text]